TFS Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

TFS Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,881	Closed	-$471K	–	830
2017 Q1	$471K	Buy	+3,881	New	+$500K	0.15%	240

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TFS Capital's ALXN Position: Q2 2017 in Review

TFS Capital sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 3,881 shares — an estimated $471K sold.

TFS Capital first reported a position in ALXN in Q1 2017 and held it in 1 quarter. The position peaked at $471K in Q1 2017. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

TFS Capital reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 3,881 Alexion Pharmaceuticals shares in Q2 2017, an estimated $471K.
TFS Capital first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 1 quarter.
TFS Capital's Alexion Pharmaceuticals position peaked at $471K in Q1 2017.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.